GAINERS

[dalmore]

RVX.to Will be sold by March 12th
Resverlogix

Resverlogix Corporation is a Canadian biotechnology company engaged in the discovery and development of biopharmaceuticals. Combining expertise with innovation, Resverlogix's NEXVAS™ Program applies advanced medical research to develop therapies that increase high-density lipoprotein (HDL), the "good cholesterol," to treat cardiovascular diseases. The TGF-beta Shield™ Program utilizes an immunomodulating therapy to target cancers and fibrotic diseases. Resverlogix Corp. is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies to prolong and enhance human life.

Will be sold by March 12th at the start of human trials

Talks ongoing with the major drug companies

There was a financing announced this week which is (imo) holding the price down

robtv interview link below
8:50 AM ET
The Street
Power Breakfast

Donald McCaffrey, president and CEO, Resverlogix
Duration: 6 m 28 s Play

http://www.robtv.com/shows/past_archive.tv?day=wed

pfzier's solution failed
lpx solution failed

There is lots of interest by big pharma
Could be a big one

http://stockcharts.com/h-sc/ui?s=RVX.TO&p=D&yr=0&mn=3&dy=0&id=p89380664454&a....


Financing closed on Friday....

Resverlogix closes $17-million (U.S.) debt financing
Resverlogix Corp (C-RVX) - News Release
Resverlogix closes $17-million (U.S.) debt financing

2007-01-05 07:16 MT - News Release
Shares issued 24,069,031
RVX Close 2007-01-04 C$ 14.15


Mr. Kenneth Lebioda reports

RESVERLOGIX ANNOUNCES CLOSING OF US $17M FINANCING

Resverlogix Corp., on Jan. 4, 2007, sold and issued to certain institutional investors, in the total, approximately $17-million (U.S.) of senior secured convertible promissory notes due Jan. 4, 2010, and accompanying warrants to purchase, in the total, approximately 408,647 common shares of Resverlogix. The notes initially have an 8-per-cent interest rate payable semi-annually in arrears and are convertible into approximately 1.63 million common shares of Resverlogix at a conversion price of $12.07 per share, subject to certain adjustments. The notes are convertible any time at the option of the noteholders or, subject to certain conditions set forth in the notes, by Resverlogix. The warrants have an exercise price of $15.09 (Canadian) per share, subject to certain adjustments. Oppenheimer & Co. Inc. acted as placement agent and Caris & Co. acted as co-agent for the offering.

The notes, warrants and the common shares underlying the notes and warrants will not be registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States unless registered under the Securities Act of 1933, as amended or unless an exemption from registration is available. Also, unless permitted under Canadian securities legislation, the holders of the notes, warrants and common shares underlying the notes and warrants will not be able to trade the notes, warrants or common shares underlying the notes and warrants until May 5, 2007. This news shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

We seek Safe Harbor.

(Not sure if you caught this on chat. The CEO said he want $60us at the recent AGM, and there are bids ongoing right now. That figure was before Pzfier's & LPX's recent failures. I'm in @ $14 on Thursday)